Preclinical models of EGFR wild-type HNSCC and lung cancer producing high levels of amphiregulin evaluated by ELISA were more likely to be growth inhibited in response to both gefitinib and cetuximab75. Here, EGFR is linked to head and neck squamous cell carcinoma.